Lexicon Pharmaceuticals to Slash 60% of Jobs, Close Commercial Operations as Part of Reorganization

Dow Jones11-22

By Adriano Marchese

Lexicon Pharmaceuticals said that it will lay off 60% of its staff and eliminate its commercial operations as part of a broader restructuring effort.

The biopharmaceutical company said Friday that the decisions are part of an effort to preserve its cash and focus its resources on advancing its clinical development pipeline.

"This prioritization of investment is designed to advance the research and development programs that have the greatest potential for value creation and patient impact," the company said.

Recently, Lexicon received a "deficiencies preclude discussion" letter from the Food and Drug Administration regarding a new drug application for its insulin therapy Zynquista, or Sotagliflozin, which precluded discussion of labeling and post-marketing requirements and commitments.

The restructuring will eliminate its commercial field team and reduce the size of other functions across the business, including promotional activity for its other drugs, Inpefa and Zynquista.

It will also eliminate 60% of its employees, with the most being let go by the end of the year.

The moves are expected to save the company $100 million in 2025, which is in addition to the $40 million previously expected.

The company will continue to focus on its pipeline of candidates, it said.

Shares fell over 14% in premarket trading to 66 cents.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

November 22, 2024 08:04 ET (13:04 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485539250?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-22 21:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485539250","market":"sh","top_or_hot":-1,"title":"Lexicon Pharmaceuticals to Slash 60% of Jobs, Close Commercial Operations as Part of Reorganization","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Lexicon Pharmaceuticals said that it will lay off 60% of its staff and eliminate its commercial operations as part of a broader restructuring effort. \n</p>\n<p>\n  The biopharmaceutical company said Friday that the decisions are part of an effort to preserve its cash and focus its resources on advancing its clinical development pipeline. \n</p>\n<p>\n  \"This prioritization of investment is designed to advance the research and development programs that have the greatest potential for value creation and patient impact,\" the company said. \n</p>\n<p>\n  Recently, Lexicon received a \"deficiencies preclude discussion\" letter from the Food and Drug Administration regarding a new drug application for its insulin therapy Zynquista, or Sotagliflozin, which precluded discussion of labeling and post-marketing requirements and commitments. \n</p>\n<p>\n  The restructuring will eliminate its commercial field team and reduce the size of other functions across the business, including promotional activity for its other drugs, Inpefa and Zynquista. \n</p>\n<p>\n  It will also eliminate 60% of its employees, with the most being let go by the end of the year. \n</p>\n<p>\n  The moves are expected to save the company $100 million in 2025, which is in addition to the $40 million previously expected. \n</p>\n<p>\n  The company will continue to focus on its pipeline of candidates, it said. \n</p>\n<p>\n  Shares fell over 14% in premarket trading to 66 cents. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 22, 2024 08:04 ET (13:04 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lexicon Pharmaceuticals to Slash 60% of Jobs, Close Commercial Operations as Part of Reorganization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLexicon Pharmaceuticals to Slash 60% of Jobs, Close Commercial Operations as Part of Reorganization\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-22 21:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Adriano Marchese \n\n\n \n\n\n  Lexicon Pharmaceuticals said that it will lay off 60% of its staff and eliminate its commercial operations as part of a broader restructuring effort. \n\n\n  The ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LXRX","symbol_name":"莱斯康制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2485539250","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485539250","pubTimestamp":1732280640,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Lexicon Pharmaceuticals said that it will lay off 60% of its staff and eliminate its commercial operations as part of a broader restructuring effort.The biopharmaceutical company said Friday that the decisions are part of an effort to preserve its cash and focus its resources on advancing its clinical development pipeline.\"This prioritization of investment is designed to advance the research and development programs that have the greatest potential for value creation and patient impact,\" the company said.Recently, Lexicon received a \"deficiencies preclude discussion\" letter from the Food and Drug Administration regarding a new drug application for its insulin therapy Zynquista, or Sotagliflozin, which precluded discussion of labeling and post-marketing requirements and commitments.The restructuring will eliminate its commercial field team and reduce the size of other functions across the business, including promotional activity for its other drugs, Inpefa and Zynquista.It will also eli","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LXRX":"莱斯康制药","BK4139":"生物科技"},"translate_title":"作为重组的一部分，Lexicon Pharmaceuticals将裁员60%并关闭商业业务","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LXRX":1},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Lexicon Pharmaceuticals said that it will lay off 60% of its staff and eliminate its commercial operations as part of a broader restructuring effort. \n\n\n  The biopharmaceutical company said Friday that the decisions are part of an effort to preserve its cash and focus its resources on advancing its clinical development pipeline. \n\n\n  \"This prioritization of investment is designed to advance the research and development programs that have the greatest potential for value creation and patient impact,\" the company said. \n\n\n  Recently, Lexicon received a \"deficiencies preclude discussion\" letter from the Food and Drug Administration regarding a new drug application for its insulin therapy Zynquista, or Sotagliflozin, which precluded discussion of labeling and post-marketing requirements and commitments. \n\n\n  The restructuring will eliminate its commercial field team and reduce the size of other functions across the business, including promotional activity for its other drugs, Inpefa and Zynquista. \n\n\n  It will also eliminate 60% of its employees, with the most being let go by the end of the year. \n\n\n  The moves are expected to save the company $100 million in 2025, which is in addition to the $40 million previously expected. \n\n\n  The company will continue to focus on its pipeline of candidates, it said. \n\n\n  Shares fell over 14% in premarket trading to 66 cents. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 22, 2024 08:04 ET (13:04 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"Shareholding Changes","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485539250"}